



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2012	2011	% Change			2012	2011	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>CONSUMER SEGMENT <sup>(2)</sup></b>										
<b><u>BABY CARE</u></b>										
US	\$ 106	105	1.0%	1.0%	-	\$ 205	210	-2.4%	-2.4%	-
Intl	472	493	-4.3%	3.5%	-7.8%	913	949	-3.8%	1.7%	-5.5%
WW	578	598	-3.3%	3.2%	-6.5%	1,118	1,159	-3.5%	1.0%	-4.5%
<b><u>ORAL CARE</u></b>										
US	159	158	0.6%	0.6%	-	314	321	-2.2%	-2.2%	-
Intl	249	241	3.3%	11.9%	-8.6%	481	469	2.6%	8.5%	-5.9%
WW	408	399	2.3%	7.5%	-5.2%	795	790	0.6%	4.1%	-3.5%
<b><u>OTC/NUTRITIONALS</u></b>										
US	336	330	1.8%	1.8%	-	717	727	-1.4%	-1.4%	-
Intl	696	753	-7.6%	0.1%	-7.7%	1,419	1,485	-4.4%	0.9%	-5.3%
WW	1,032	1,083	-4.7%	0.6%	-5.3%	2,136	2,212	-3.4%	0.2%	-3.6%
<b><u>SKIN CARE</u></b>										
US	471	449	4.9%	4.9%	-	924	875	5.6%	5.6%	-
Intl	442	480	-7.9%	-0.3%	-7.6%	896	953	-6.0%	-1.0%	-5.0%
WW	913	929	-1.7%	2.2%	-3.9%	1,820	1,828	-0.4%	2.2%	-2.6%
<b><u>WOMEN'S HEALTH</u></b>										
US	80	121	-33.9%	-33.9%	-	173	246	-29.7%	-29.7%	-
Intl	322	356	-9.6%	-0.2%	-9.4%	638	690	-7.5%	-0.8%	-6.7%
WW	402	477	-15.7%	-8.7%	-7.0%	811	936	-13.4%	-8.5%	-4.9%
<b><u>WOUND CARE/OTHER</u></b>										
US	161	176	-8.5%	-8.5%	-	296	305	-3.0%	-3.0%	-
Intl	125	131	-4.6%	2.8%	-7.4%	238	245	-2.9%	2.3%	-5.2%
WW	286	307	-6.8%	-3.7%	-3.1%	534	550	-2.9%	-0.6%	-2.3%
<b><u>TOTAL CONSUMER</u></b>										
US	1,313	1,339	-1.9%	-1.9%	-	2,629	2,684	-2.0%	-2.0%	-
Intl	2,306	2,454	-6.0%	2.0%	-8.0%	4,585	4,791	-4.3%	1.2%	-5.5%
WW	\$ 3,619	3,793	-4.6%	0.6%	-5.2%	\$ 7,214	7,475	-3.5%	0.0%	-3.5%

See footnotes at end of schedule

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	SECOND QUARTER					SIX MONTHS				
	2012	2011	% Change			2012	2011	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>PHARMACEUTICAL SEGMENT <sup>(2) (4)</sup></b>										
<b>IMMUNOLOGY</b>										
US	\$ 1,471	1,524	-3.5%	-3.5%	-	\$ 2,924	2,960	-1.2%	-1.2%	-
Intl	448	131	*	*	-8.1%	890	275	*	*	-5.2%
WW	1,919	1,655	16.0%	18.2%	-2.2%	3,814	3,235	17.9%	19.1%	-1.2%
<b>REMICADE</b>										
US	890	836	6.5%	6.5%	-	1,772	1,624	9.1%	9.1%	-
US Exports <sup>(3)</sup>	366	527	-30.6%	-30.6%	-	744	1,017	-26.8%	-26.8%	-
Intl	267	8	*	*	-8.3%	528	15	*	*	-5.3%
WW	1,523	1,371	11.1%	12.7%	-1.6%	3,044	2,656	14.6%	15.6%	-1.0%
<b>SIMPONI</b>										
US	63	61	3.3%	3.3%	-	127	114	11.4%	11.4%	-
Intl	62	6	*	*	-5.8%	114	48	*	*	-8.6%
WW	125	67	86.6%	89.5%	-2.9%	241	162	48.8%	51.3%	-2.5%
<b>STELARA</b>										
US	152	100	52.0%	52.0%	-	281	205	37.1%	37.1%	-
Intl	96	76	26.3%	35.1%	-8.8%	188	137	37.2%	45.5%	-8.3%
WW	248	176	40.9%	45.7%	-4.8%	469	342	37.1%	40.4%	-3.3%
<b>OTHER IMMUNOLOGY</b>										
US	-	-	-	-	-	-	-	-	-	-
Intl	23	41	-43.9%	-39.2%	-4.7%	60	75	-20.0%	-16.6%	-3.4%
WW	23	41	-43.9%	-39.2%	-4.7%	60	75	-20.0%	-16.6%	-3.4%
<b>INFECTIOUS DISEASES</b>										
US	237	351	-32.5%	-32.5%	-	479	975	-50.9%	-50.9%	-
Intl	551	477	15.5%	26.0%	-10.5%	1,064	784	35.7%	44.3%	-8.6%
WW	788	828	-4.8%	1.3%	-6.1%	1,543	1,759	-12.3%	-8.5%	-3.8%
<b>INTELENCE</b>										
US	42	38	10.5%	10.5%	-	85	76	11.8%	11.8%	-
Intl	49	41	19.5%	30.4%	-10.9%	86	72	19.4%	27.4%	-8.0%
WW	91	79	15.2%	20.8%	-5.6%	171	148	15.5%	19.4%	-3.9%
<b>LEVAQUIN/FLOXIN</b>										
US	7	149	-95.3%	-95.3%	-	25	571	-95.6%	-95.6%	-
Intl	9	10	-10.0%	-2.7%	-7.3%	20	22	-9.1%	-3.9%	-5.2%
WW	16	159	-89.9%	-89.4%	-0.5%	45	593	-92.4%	-92.2%	-0.2%
<b>PREZISTA</b>										
US	166	128	29.7%	29.7%	-	326	254	28.3%	28.3%	-
Intl	207	185	11.9%	22.6%	-10.7%	371	325	14.2%	22.2%	-8.0%
WW	373	313	19.2%	25.5%	-6.3%	697	579	20.4%	24.9%	-4.5%
<b>OTHER INFECTIOUS DISEASES</b>										
US	22	36	-38.9%	-38.9%	-	43	74	-41.9%	-41.9%	-
Intl	286	241	18.7%	29.1%	-10.4%	587	365	60.8%	70.3%	-9.5%
WW	308	277	11.2%	20.2%	-9.0%	630	439	43.5%	51.4%	-7.9%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	<b>SECOND QUARTER</b>					<b>SIX MONTHS</b>				
	<b>2012</b>	<b>2011</b>	<b>% Change</b>			<b>2012</b>	<b>2011</b>	<b>% Change</b>		
			<b>Reported</b>	<b>Operational <sup>(1)</sup></b>	<b>Currency</b>			<b>Reported</b>	<b>Operational <sup>(1)</sup></b>	<b>Currency</b>
<b>NEUROSCIENCE</b>										
US	658	684	-3.8%	-3.8%	-	1,332	1,372	-2.9%	-2.9%	-
Intl	1,056	1,096	-3.6%	3.2%	-6.8%	2,029	2,153	-5.8%	-1.3%	-4.5%
WW	1,714	1,780	-3.7%	0.5%	-4.2%	3,361	3,525	-4.7%	-1.9%	-2.8%
<b>CONCERTA/METHYLPHENIDATE</b>										
US	146	234	-37.6%	-37.6%	-	343	488	-29.7%	-29.7%	-
Intl	122	115	6.1%	14.0%	-7.9%	233	223	4.5%	10.1%	-5.6%
WW	268	349	-23.2%	-20.6%	-2.6%	576	711	-19.0%	-17.2%	-1.8%
<b>INVEGA</b>										
US	76	76	0.0%	0.0%	-	145	145	0.0%	0.0%	-
Intl	66	52	26.9%	33.6%	-6.7%	118	103	14.6%	18.8%	-4.2%
WW	142	128	10.9%	13.6%	-2.7%	263	248	6.0%	7.8%	-1.8%
<b>INVEGA SUSTENNA/ XEPLION</b>										
US	120	70	71.4%	71.4%	-	220	135	63.0%	63.0%	-
Intl	75	7	*	*	-8.8%	136	7	*	*	-6.2%
WW	195	77	*	*	-3.4%	356	142	*	*	-2.4%
<b>RISPERDAL CONSTA</b>										
US	110	110	0.0%	0.0%	-	223	224	-0.4%	-0.4%	-
Intl	245	294	-16.7%	-9.3%	-7.4%	493	584	-15.6%	-10.5%	-5.1%
WW	355	404	-12.1%	-6.7%	-5.4%	716	808	-11.4%	-7.7%	-3.7%
<b>OTHER NEUROSCIENCE</b>										
US	206	194	6.2%	6.2%	-	401	380	5.5%	5.5%	-
Intl	548	628	-12.7%	-7.3%	-5.4%	1,049	1,236	-15.1%	-11.7%	-3.4%
WW	754	822	-8.3%	-4.2%	-4.1%	1,450	1,616	-10.3%	-7.7%	-2.6%
<b>ONCOLOGY</b>										
US	119	93	28.0%	28.0%	-	226	157	43.9%	43.9%	-
Intl	467	459	1.7%	11.2%	-9.5%	956	834	14.6%	21.8%	-7.2%
WW	586	552	6.2%	14.1%	-7.9%	1,182	991	19.3%	25.3%	-6.0%
<b>DOXIL/CAELYX</b>										
US	6	56	-89.3%	-89.3%	-	13	120	-89.2%	-89.2%	-
Intl	7	82	-91.5%	-89.9%	-1.6%	24	157	-84.7%	-83.4%	-1.3%
WW	13	138	-90.6%	-89.7%	-0.9%	37	277	-86.6%	-85.9%	-0.7%
<b>VELCADE</b>										
US	-	-	-	-	-	-	-	-	-	-
Intl	318	347	-8.4%	-0.1%	-8.3%	671	627	7.0%	13.4%	-6.4%
WW	318	347	-8.4%	-0.1%	-8.3%	671	627	7.0%	13.4%	-6.4%
<b>ZYTIGA</b>										
US	113	37	*	*	-	213	37	*	*	-
Intl	119	12	*	*	-10.0%	219	17	*	*	-7.1%
WW	232	49	*	*	-5.1%	432	54	*	*	-3.6%
<b>OTHER ONCOLOGY</b>										
US	-	-	-	-	-	-	-	-	-	-
Intl	23	18	27.8%	36.4%	-8.6%	42	33	27.3%	33.2%	-5.9%
WW	23	18	27.8%	36.4%	-8.6%	42	33	27.3%	33.2%	-5.9%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	<b>SECOND QUARTER</b>					<b>SIX MONTHS</b>				
	<b>2012</b>	<b>2011</b>	<b>% Change</b>			<b>2012</b>	<b>2011</b>	<b>% Change</b>		
			<b>Reported</b>	<b>Operational <sup>(1)</sup></b>	<b>Currency</b>			<b>Reported</b>	<b>Operational <sup>(1)</sup></b>	<b>Currency</b>
<b>TOTAL OTHER</b>										
US	609	587	3.7%	3.7%	-	1,159	1,166	-0.6%	-0.6%	-
Intl	675	831	-18.8%	-11.8%	-7.0%	1,365	1,616	-15.5%	-10.9%	-4.6%
WW	1,284	1,418	-9.4%	-5.3%	-4.1%	2,524	2,782	-9.3%	-6.6%	-2.7%
<b>ACIPHEX/PARIET</b>										
US	104	101	3.0%	3.0%	-	200	210	-4.8%	-4.8%	-
Intl	128	146	-12.3%	-2.8%	-9.5%	254	276	-8.0%	-1.5%	-6.5%
WW	232	247	-6.1%	-0.5%	-5.6%	454	486	-6.6%	-2.9%	-3.7%
<b>PROCIT/EPREX</b>										
US	232	257	-9.7%	-9.7%	-	436	447	-2.5%	-2.5%	-
Intl	169	218	-22.5%	-14.9%	-7.6%	341	425	-19.8%	-14.5%	-5.3%
WW	401	475	-15.6%	-12.1%	-3.5%	777	872	-10.9%	-8.3%	-2.6%
<b>OTHER</b>										
US	273	229	19.2%	19.2%	-	523	509	2.8%	2.8%	-
Intl	378	467	-19.1%	-13.2%	-5.9%	770	915	-15.8%	-12.1%	-3.7%
WW	651	696	-6.5%	-2.6%	-3.9%	1,293	1,424	-9.2%	-6.8%	-2.4%
<b>TOTAL PHARMACEUTICAL</b>										
US	3,094	3,239	-4.5%	-4.5%	-	6,120	6,630	-7.7%	-7.7%	-
Intl	3,197	2,994	6.8%	15.5%	-8.7%	6,304	5,662	11.3%	17.3%	-6.0%
WW	<b>\$ 6,291</b>	<b>6,233</b>	<b>0.9%</b>	<b>5.1%</b>	<b>-4.2%</b>	<b>\$ 12,424</b>	<b>12,292</b>	<b>1.1%</b>	<b>3.9%</b>	<b>-2.8%</b>

See footnotes at end of schedule

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	<b>SECOND QUARTER</b>					<b>SIX MONTHS</b>				
	2012	2011	% Change			2012	2011	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>MEDICAL DEVICES AND DIAGNOSTICS</b> <sup>(2)(4)</sup>										
<u>CARDIOVASCULAR CARE</u>										
US	\$ 195	210	-7.1%	-7.1%	-	\$ 371	452	-17.9%	-17.9%	-
Intl	309	377	-18.0%	-13.1%	-4.9%	615	770	-20.1%	-17.2%	-2.9%
WW	504	587	-14.1%	-10.9%	-3.2%	986	1,222	-19.3%	-17.5%	-1.8%
<u>DIABETES CARE</u>										
US	337	333	1.2%	1.2%	-	689	644	7.0%	7.0%	-
Intl	336	348	-3.4%	4.6%	-8.0%	654	674	-3.0%	2.5%	-5.5%
WW	673	681	-1.2%	2.9%	-4.1%	1,343	1,318	1.9%	4.7%	-2.8%
<u>DIAGNOSTICS</u>										
US	258	281	-8.2%	-8.2%	-	511	546	-6.4%	-6.4%	-
Intl	256	269	-4.8%	0.8%	-5.6%	515	525	-1.9%	1.6%	-3.5%
WW	514	550	-6.5%	-3.8%	-2.7%	1,026	1,071	-4.2%	-2.5%	-1.7%
<u>GENERAL SURGERY</u>										
US	602	621	-3.1%	-3.1%	-	1,195	1,217	-1.8%	-1.8%	-
Intl	1,038	1,079	-3.8%	3.1%	-6.9%	2,070	2,104	-1.6%	2.8%	-4.4%
WW	1,640	1,700	-3.5%	0.9%	-4.4%	3,265	3,321	-1.7%	1.1%	-2.8%
<u>INFECTION PREVENTION/OTHER</u>										
US	99	98	1.0%	1.0%	-	215	193	11.4%	11.4%	-
Intl	131	134	-2.2%	3.3%	-5.5%	259	255	1.6%	4.8%	-3.2%
WW	230	232	-0.9%	2.3%	-3.2%	474	448	5.8%	7.6%	-1.8%
<u>ORTHOPAEDICS</u>										
US	873	770	13.4%	13.4%	-	1,656	1,581	4.7%	4.7%	-
Intl	755	699	8.0%	14.8%	-6.8%	1,465	1,391	5.3%	9.5%	-4.2%
WW	1,628	1,469	10.8%	14.0%	-3.2%	3,121	2,972	5.0%	6.9%	-1.9%
<u>SPECIALTY SURGERY</u>										
US	336	311	8.0%	8.0%	-	663	607	9.2%	9.2%	-
Intl	310	309	0.3%	7.6%	-7.3%	611	590	3.6%	8.4%	-4.8%
WW	646	620	4.2%	7.8%	-3.6%	1,274	1,197	6.4%	8.8%	-2.4%
<u>VISION CARE</u>										
US	253	245	3.3%	3.3%	-	530	501	5.8%	5.8%	-
Intl	477	487	-2.1%	1.2%	-3.3%	957	953	0.4%	1.9%	-1.5%
WW	730	732	-0.3%	1.9%	-2.2%	1,487	1,454	2.3%	3.3%	-1.0%
<b>TOTAL MEDICAL DEVICES AND DIAGNOSTICS</b>										
US	2,953	2,869	2.9%	2.9%	-	5,830	5,741	1.6%	1.6%	-
Intl	3,612	3,702	-2.4%	3.8%	-6.2%	7,146	7,262	-1.6%	2.2%	-3.8%
WW	\$ 6,565	6,571	-0.1%	3.4%	-3.5%	\$ 12,976	13,003	-0.2%	1.9%	-2.1%

\* Percentage greater than 100%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Reported as U.S. sales

(4) Prior year amounts have been reclassified to conform to current year product disclosure